Podcast: PET tracers’ role in precision medicine paradigms for neurodegenerative diseases

Swiss biotech AC Immune discusses its PET tracer's potential in realising precision medicine approaches to neurodegenerative diseases. Swiss biotech AC Immune discusses its PET tracer's potential in realising precision medicine approaches to neurodegenerative diseases. AC Immune outlines how its ACI-19626 PET tracer could play a role in diagnosis and precision medicine approaches to neurodegenerative disease including frontotemporal dementia and Parkinson’s disease. Credit: Lightspring / Shutterstock.com In March 2026, Swiss biotech AC Immune presented Phase I data including the first in vivo images of TDP-43 pathology in the human brain, detected using its first-in-class positron emission tomography (PET) tracer ACI-19626, at…

Source: Medical Device Network